Abstracts tagged "Antibodies"

Abstract Number: 809 • 2015 ACR/ARHP Annual Meeting
Patients with SLE Who Are Anti-Factor Xa IgG Positive Are Less Likely to Have Atherosclerotic Plaque
Claire-Louise Murphy¹, Sara Croca¹, Bahar Artim-Esen², Laura Hanns³, Charis Pericleous¹, Thomas McDonnell¹, Yiannis Ioannou⁴, David A. Isenberg¹, Anisur Rahman¹ and Ian Giles⁵, ¹Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ²Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³Rheumatology, Arthritis Research UK Centre for Adolescent Rheumatology, UCL Division of Medicine, London, United Kingdom, ⁴Rayne Institute, Arthritis Research UK Centre for Adolescent Rheumatology, UCL Division of Medicine, London, United Kingdom, ⁵Rayne Intitiute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom
Background/Purpose: Patients with SLE have an increased risk of cardiovascular disease (CVD), which is not fully explained by traditional risk factors and may be mediated…
Abstract Number: 823 • 2015 ACR/ARHP Annual Meeting
Anti-IFI16 Antibodies in Scleroderma Are Associated with Digital Gangrene
Zsuzsanna McMahan¹, Ami A. Shah², Dhananjay Vaidya³, Fredrick M. Wigley⁴, Antony Rosen⁵ and Livia Casciola-Rosen⁶, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Medicine, School of Medicine, Johns Hopkins, Baltimore, MD, ⁴Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Mason Lord Bldg Ctr Tower, Johns Hopkins University, School of Medicine, Baltimore, MD, ⁶Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Our aim was to examine and confirm the association between anti-IFI16 antibodies and clinical features of scleroderma. Methods: Sera from a discovery sample…
Abstract Number: 1151 • 2015 ACR/ARHP Annual Meeting
The Proteomic Profile of Histological Samples Derived from a Surgical Mouse Model of Osteoarthritis Reveals an Unexpected Mode of Action for the Anti-Aggrecanase-2 Monoclonal Antibody CRB0017
Gianfranco Caselli¹, Riccardo Chiusaroli², Michela Visintin³, Tiziana Piepoli², Ornella Letari², Adriana Grotti², Marco Lanza², Antonella De Palma⁴, Dario di Silvestre⁴, Pierluigi Mauri⁴ and Lucio Claudio Rovati², ¹Pharmacology & Toxicology, Rottapharm Biotech Srl, Monza, Italy, ²Rottapharm Biotech Srl, Monza, Italy, ³Rottapharm Biotech Srl, Trieste, Italy, ⁴Institute for Biomedical Technologies - CNR, Segrate, Italy
Background/Purpose : CRB0017 is a novel therapeutic monoclonal antibody that recognizes the spacer domain of aggrecanase-2, a key enzyme in the degradation of extracellular matrix…
Abstract Number: 1366 • 2015 ACR/ARHP Annual Meeting
Natural Antibodies, Not B Cells, Contribute to Acute Cell Death-Induced Inflammation
Hiroshi Kataoka, Rheumatology and Clinical Immunology, Sapporo City General Hospital, Sapporo, Japan
Background/Purpose: Alarmins, such as uric acid, released from dying cells activate inflammasomes and mediate dead cell-induced inflammation (Ref.). Since it is remains unknown whether or…
Abstract Number: 1772 • 2015 ACR/ARHP Annual Meeting
Anti-Pentraxin 3 Antibodies Ameliorate Disease Manifestations and Lupus-like Nephritis in New Zealand Black/New Zealand White F1 Mice
Mariele Gatto¹, Nicola Bassi¹, Anna Ghirardello¹, Roberto Luisetto¹, Silvano Bettio¹, Luca Iaccarino¹, Leonardo Punzi² and Andrea Doria², ¹Department of Medicine-DIMED, University of Padova, Padova, Italy, ²Department of Medicine - DIMED, University of Padova, Padova, Italy
Background/Purpose: Pentraxin 3 (PTX3) is an acute-phase protein released by different cell types including renal epithelial cells and immune-competent cells. PTX3 is able to either…
Abstract Number: 1858 • 2015 ACR/ARHP Annual Meeting
Serum Tartrate Resistant Acid Phosphatase (TRAP) Levels Are Decreased and Associated with Anti-Maa Antibodies in Systemic Lupus Erythematosus (SLE) Patients
Kathleen Borghoff¹, Andy Hollins², Michael J. Duryee¹, Ted R. Mikuls², Zhixin Zhang³, Kaihong Su⁴, Michelene Hearth-Holmes⁵ and Geoffrey M. Thiele⁶, ¹Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ⁴Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ⁵Division of Rheumatology, University of Nebraska College of Medicine and VA Nebraska Western Iowa Health Care System, Omaha, NE, ⁶Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Previous studies have shown that patients with systemic lupus erythematosus (SLE) are prone to systemic osteoporosis, bone loss and fracture. Paradoxically, previous studies…
Abstract Number: 1248 • 2014 ACR/ARHP Annual Meeting
Serologic and Clinical Overlap Between Sarcoidosis and the Rheumatic Autoimmume Diseases
Sabrina Qazi¹ and Marie Claire Maroun², ¹Internal Medicine-Rheumatology, Wayne State University, Detroit, MI, ²Rheumatology, Wayne State University, Detroit, MI
Background/Purpose Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized pathologically by noncaseating epithelioid cell granulomas, primarily affecting the lungs, the eye, the skin,…
Abstract Number: 730 • 2014 ACR/ARHP Annual Meeting
Prediction of Cardiac and Vascular Events in Systemic Sclerosis: Input from Endothelin-1 Type a Receptor Antibodies
Jerome Avouac¹, Gabriela Riemekasten², Christophe Meune³, Barbara Ruiz⁴ and Yannick Allanore¹, ¹Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, ²Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, ³Paris 13 University, University Hospital of Paris-Seine-Saint-Denis, Cardiology Department, Bobigny, France, ⁴Paris Descartes University, INSERM U1016, Institut Cochin, Sorbonne Paris Cité, Paris, France
Background/Purpose: Cardiac and peripheral microvascular alterations are key features of systemic sclerosis (SSc). We have previously reported that angiogenic markers can predict the cardiovascular outcomes…
Abstract Number: 320 • 2014 ACR/ARHP Annual Meeting
Autoantibodies in Juvenile Systemic Sclerosis
Katharine Moore^1,2, J. Lee Nelson^3,4, Marvin J. Fritzler⁵, Marisa S. Klein-Gitelman⁶, Ann M. Reed⁷, Tzielan C. Lee⁸ and Anne M. Stevens^1,9, ¹Pediatrics, University of Washington, Seattle, WA, ²Pediatric Rheumatology, Seattle Children's Hospital, Seattle, WA, ³University of Washington, Seattle, WA, ⁴Fred Hutchinson Cancer Research Center, Seattle, WA, ⁵Mitogen Advanced Diagnostics Laboratory, Faculty of Medicine, University of Calgary, Calgary, AB, Canada, ⁶Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁷Rheumatology, Mayo Clinic, Rochester, MN, ⁸Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁹Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: There are no known biomarkers for organ involvement, response to therapy, or prognosis in juvenile systemic sclerosis (jSSc). In adults with systemic sclerosis, a…
Abstract Number: 2924 • 2014 ACR/ARHP Annual Meeting
Clinical Utility of Random Anti-TNF Drug Level Testing and Measurement of Anti-Drug Antibodies on Long-Term Treatment Response in Rheumatoid Arthritis
Meghna Jani¹, Hector Chinoy^1,2, Richard B. Warren³, Christopher E.M Griffiths³, Ann W. Morgan⁴, Anthony G. Wilson⁵, Kimme L. Hyrich¹, John Isaacs⁶, Darren Plant^1,2 and Anne Barton^1,7, ¹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ³Dermatology Centre, University of Manchester, Manchester, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin, Ireland, ⁶Institute of Cellular Medicine, University of Newcastle, Newcastle, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose Up to 40% of RA patients on anti-TNF treatment fail to respond either due to primary inefficacy or loss of response. One explanation is…
Abstract Number: 2771 • 2014 ACR/ARHP Annual Meeting
PET-CT Imaging and Association of Ferritin Autoantibodies in Polymyalgia Rheumatica
Niklas Thomas Baerlecken¹, Torsten Witte², Marco Amedeo Cimmino³ and Dario Camellino⁴, ¹Clinical Immunology and Rheumatology, MD, Hannover, Germany, ²Medical School Hannover, MD, Hanover, Germany, ³Clinica Reumatologica, Università di Genova, Genova, Italy, ⁴Dipartimento Medicina Interna, Clinica Reumatologica, Genova, Italy
Background/Purpose Previously we described antibodies against ferritin heavy chain peptide (anti-FHCP) in sera of patients with giant cell arteritis (GCA) and/or polymyalgia rheumatic (PMR) before…
Abstract Number: 2663 • 2014 ACR/ARHP Annual Meeting
Sense of Smell, Anti-Ribosomal P Antibodies and Neuropsychiatric Manifestations in Systemic Lupus Erythematosus
Fernando Augusto Peres¹, Karina Oliveira Peliçari², Nailu A. Sinicato¹, Mariana Postal¹, Aline T. Lapa¹, Lilian Costallat³ and Simone Appenzeller⁴, ¹Medicine, State University of Campinas, Campinas, Brazil, ²State University of Campinas, Campinas, Brazil, ³Medicine, State University of Campinas, Campinas, United Kingdom, ⁴Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil
Background/Purpose Neuropsychiatric manifestations occur in 12-95% of SLE patients. Recent studies have demonstrated the high specificity of antiribosomal P antibodies for SLE. Antiribosomal P antibodies…
Abstract Number: 2652 • 2014 ACR/ARHP Annual Meeting
Headache in Patients with Systemic Lupus Erythematosus Is Associated with Reduced Cerebral Grey Matter Volume, but not with Measures of Glial Activation, Anti-NR2-, or Anti-P Antibodies
Anne B Tjensvoll¹, Maria B Lauvsnes², Shunsei Hirohata³, Jan T Kvaløy⁴, Mona K Beyer⁵, Erna Harboe⁶, Lasse G Gøransson⁶, Ole J Greve⁷ and Roald Omdal⁸, ¹Department of Neurology, Stavanger University Hospital, Stavanger, Norway, ²Department of Internal Medicine, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway, ³Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ⁴Research Department, Stavanger University Hospital, Stavanger, Norway, ⁵Department of Radiology and Nuclear medicine, Oslo University Hospital, National Hospital, Oslo, Norway, ⁶Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁷Department of Radiology, Stavanger University Hospital, Stavanger, Norway, ⁸Department of Internal Medicin, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway
Background/Purpose: Headache, especially migraine, is frequent and one of the most common neuropsychiatric manifestations in systemic lupus erythematosus (SLE). A possible mechanism for this is…
Abstract Number: 2539 • 2014 ACR/ARHP Annual Meeting
Antibodies to Human Interferon-Inducible Protein-16 Are Present in Primary Sjögren’s Syndrome and Systemic Lupus, but Are Rare in Dermatomyositis
Alan N. Baer¹, Michelle Petri², David Fiorentino³, Tao Wang⁴, Jungsan Sohn⁴, Antony Rosen¹ and Livia Casciola-Rosen⁵, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ⁴Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Interferon inducible protein-16 (IFI16) is an intracellular DNA receptor involved in innate immunity. We evaluated the frequency and clinical significance of anti-IFI16 antibodies in…
Abstract Number: 2350 • 2014 ACR/ARHP Annual Meeting
A Humanized Monoclonal Antibody Raised Against a Heat Shock Protein Epitope Suppresses Autoimmune Inflammatory Diseases By Skewing the Immune System Selectively Towards an Anti-Inflammatory Response
Yaakov Naparstek¹, Rina Ulmansky², Galia Katzavian³, Ronit Meyuhas³, Eli Moallem⁴, Shira Yair³, Dorit Landstein³ and Virginie Loeb³, ¹Medicine, Hadassah - Hebrew University Medical Center, Jerusalem, Israel, ²Hadassah - Hebrew University Medical Center, Jerusalem, Israel, ³ProtAb Ltd., Jerusalem, Israel, ⁴Dept. of Medicine, Hadassah - Hebrew University Medical Center, Jerusalem, Israel
Background/Purpose We have previously shown that resistance to Adjuvant Arthritis (AA) is due to the presence of anti-heat shock protein (HSP) antibodies, directed at peptide-6,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].